drugset / Trial / NCT04922788
Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate the safety, immunogenicity, and efficacy of Nanocovax vaccine in volunteer subjects 18 years of age and older.
Timeline
- Start
- 2021-06-07
- Primary completion
- 2022-07-20
- Completion
- 2022-07-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nanocovax | Vaccine | 25 ug | Intramuscular |